Clinical trial
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary…
NCT00066729 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00066729 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| Official title | A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Biological |
| Interventions | NY-ESO-1 peptide vaccine |
| Enrollment | 9 |
| Start date | Jun 23, 2003 |
| Primary completion | May 9, 2006 |
| Completion | Aug 1, 2013 |
| First posted | Aug 7, 2003 |
| Last update posted | Oct 4, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: